The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
Open accessAbstract
Immune checkpoint blockade therapy has demonstrated promising clinical outcomes for multiple cancer types. However, the emergence of resistance as well as inadequate biomarkers for patient stratification have largely limited the clinical benefits. Here, we showed that tumors with high TYRO3 expression exhibited anti-programmed cell death protein 1/programmed death ligand 1 (anti-PD-1/PD-L1) resistance in a syngeneic mouse model and in patients who received anti-PD-1/PD-L1 therapy. Mechanistically, TYRO3 inhibited tumor cell ferroptosis triggered by anti-PD-1/PD-L1 and facilitated the development of a protumor microenvironment by reducing the M1/M2 macrophage ratio, resulting in resistance to anti-PD-1/PD-L1 therapy. Inhibition of TYRO3 promoted tumor ferroptosis and sensitized resistant tumors to anti-PD-1 therapy. Collectively, our findings suggest that TYRO3 could serve as a predictive biomarker for patient selection and a promising therapeutic target to overcome anti-PD-1/PD-L1 resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0136-1 · Cited by 5,179
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Ferroptosis: process and function
Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., & Tang, D. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.158 · Cited by 3,727
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Self-citationThe prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Self-citationCD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
Wang, W., Green, M., Choi, J. E., Gijón, M., Kennedy, P. D., Johnson, J. K., Liao, P., Lang, X., Kryczek, I., Sell, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1170-y · Cited by 2,880
NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis
Dodson, M., Castro-Portuguez, R., & Zhang, D. D. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101107 · Cited by 2,435
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401 · cited 2×
“To further determine the correlation between TYRO3 and anti–PD-1 therapeutic outcomes, we analyzed TYRO3 expression in RNA-Seq data from patients with melanoma who received anti– PD-1 therapy (12) and found that those with resistant tumors had significantly higher TYRO3 expression levels than did patients whose tumors…”
BackgroundMethodSun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., & Tang, D. (2016) · Hepatology · doi:10.1002/hep.28251 · Cited by 2,012 · cited 1×
“NRF2, a key mediator in blocking ferroptosis (24, 25), activates the transcription of ferroptosis-inhibitory genes, including 4F2 cell-surface antigen heavy chain (SLC3A2), cystine/glutamate transporter (SLC7A11), ferritin light chain (FTL), ferritin heavy chain (FTH1), glutathione peroxidase 4 (GPX4), ferroportin (SL…”
BackgroundBlockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R., Weber, J. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz011 · Cited by 945
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00002-x · Cited by 751
Martin, D., Rojo, A. I., Salinas, M., Diaz, R., Gallardo, G., Alam, J., de Galarreta, C. M. R., & Cuadrado, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309660200 · Cited by 700
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
Graham, D. K., DeRyckere, D., Davies, K. D., & Earp, H. S. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3847 · Cited by 698
The release and activity of HMGB1 in ferroptosis
Wen, Q., Liu, J., Kang, R., Zhou, B., & Tang, D. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.090 · Cited by 672
Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy518 · Cited by 637
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Li, C.-W., Lim, S.-O., Chung, E. M., Kim, Y.-S., Park, A. H., Yao, J., Cha, J.-H., Xia, W., Chan, L.-C., Kim, T., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.009 · Cited by 602
Self-citationThe E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Paolino, M., Choidas, A., Wallner, S., Pranjic, B., Uribesalgo, I., Loeser, S., Jamieson, A. M., Langdon, W. Y., Ikeda, F., Fededa, J. P., et al. (2014) · Nature · doi:10.1038/nature12998 · Cited by 456
Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration
Abdalkader, M., Lampinen, R., Kanninen, K. M., Malm, T. M., & Liddell, J. R. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00466 · Cited by 423
Targeting RTK Signaling Pathways in Cancer
Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 380
Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525360113 · Cited by 357
Tsou, W.-I., Nguyen, K.-Q. N., Calarese, D. A., Garforth, S. J., Antes, A. L., Smirnov, S. V., Almo, S. C., Birge, R. B., & Kotenko, S. V. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.569020 · Cited by 237
Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis
Reißfelder, C., Stamova, S., Gossmann, C., Braun, M., Bonertz, A., Walliczek, U., Grimm, M., Rahbari, N. N., Koch, M., Saadati, M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74894 · Cited by 146
Metabolic networks in ferroptosis (Review)
Hao, S., Liang, B., Huang, Q., Dong, S., Wu, Z., He, W., & Shi, M. (2018) · Oncology Letters · doi:10.3892/ol.2018.8066 · Cited by 146
Holtzhausen, A., Harris, W. P., Ubil, E., Hunter, D. M., Zhao, J., Zhang, Y., Zhang, D., Liu, Q., Wang, X., Graham, D. K., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0008 · Cited by 145
Kasikara, C., Davra, V., Calianese, D. C., Geng, K., Spires, T. E., Quigley, M. M., Wichroski, M. J., Sriram, G., Suárez-López, L., Yaffe, M. B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2614 · Cited by 125
The Emerging Role of TYRO3 as a Therapeutic Target in Cancer
Smart, S. K., Vasileiadi, E., Wang, X., DeRyckere, D., & Graham, D. K. (2018) · Cancers · doi:10.3390/cancers10120474 · Cited by 99
Yokoyama, Y., Lew, E. D., Seelige, R., Tindall, E. A., Walsh, C. T., Fagan, P. C., Lee, J. Y., Nevarez, R., Oh, J., Tucker, K. D., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2022 · Cited by 93
Chien, C.-W., Hou, P.-C., Wu, H.-C., Chang, Y.-L., Lin, S.-C., Lin, S.-C., Lin, B.-W., Lee, J.-C., Chang, Y.-J., Sun, H. S., et al. (2016) · Oncogene · doi:10.1038/onc.2016.120 · Cited by 71
Mavratzas, A., Seitz, J., Smetanay, K., Schneeweiß, A., Jäger, D., & Fremd, C. (2019) · Future Oncology · doi:10.2217/fon-2019-0468 · Cited by 69
Brown, J. E., Krodel, M., Pazos, M., Lai, C., & Prieto, A. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036800 · Cited by 58
The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments
Vâjâitu, C., DRAGHICI, C. C., Solomon, I., Lisievici, C. V., Popa, A. V., Lupu, M., Căruntu, C., Constantin, M. M., & Voiculescu, V. M. (2018) · Journal of Immunology Research · doi:10.1155/2018/4625472 · Cited by 32
Cluster stability in the analysis of mass cytometry data
Melchiotti, R., Grácio, F., Kordasti, S. Y., Todd, A. K., & de Rinaldis, E. (2016) · Cytometry Part A · doi:10.1002/cyto.a.23001 · Cited by 30
Cited by
Targeting Ferroptosis as a Vulnerability in Cancer
Lei, G., Zhuang, L., & Gan, B. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00459-0 · Cited by 2,252
Ferroptosis in cancer therapy: a novel approach to reversing drug resistance
Zhang, C., Liu, X., Jin, S., Chen, Y., & Guo, R. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01530-y · Cited by 1,332
Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies
Zhou, Q., Meng, Y., Li, D., Yao, L., Le, J., Liu, Y., Sun, Y., Zeng, F., Chen, X., & Deng, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01769-5 · Cited by 890
Ferroptosis in infection, inflammation, and immunity
Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20210518 · Cited by 824
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Metadata
- Authors
- Jiang, Z., Lim, S.-O., Yan, M., Hsu, J. L., Yao, J., Wei, Y., Chang, S.-S., Yamaguchi, H., Lee, H.-H., Ke, B., Hsu, J.-M., Chan, L.-C., Hortobagyi, G. N., Yang, L., Lin, C., Yu, D., & Hung, M.-C.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-04-15
- Volume
- 131
- Issue
- 8
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3156708696
- Cited by
- 325
- References
- 35
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.